DLA Piper LLP (US)
Dihydrofolate reductase inhibitors
The present disclosure provides compounds of Formula I:or a pharmaceutically acceptable salt thereof, wherein R5, R6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.
Trius Therapeutics, Inc.
C A A C A C A
C07D A61P A61P C07D A61P C07D A61P
inventional inventional inventional inventional inventional inventional inventional
Michael Thanh Zhiyong Christopher J. Mark Mark Michael Mark Les Lucy Aguirre Junhu John Xiaoming
Jung Lam Chen Creighton Stidham Cunningham Trzoss Hilgers Tari Kohnen Zhang Finn Li